ERA Congress 2025 marked a pivotal moment in nephrology this year, bringing together over 9,000 global experts to explore ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...